Nuvalent, Inc.
Precision-oncology biotech developing brain-penetrant kinase inhibitors designed to address resistance and selectivity limitations.
Precision oncology / lung cancer · Targeted small-molecule kinase inhibitors · NDA under FDA review + Phase 3